Actively Recruiting
AGE-ING (Assessment of Geriatric Evaluations Impact on New AML Guidance) Study
Led by Abramson Cancer Center at Penn Medicine · Updated on 2025-08-07
100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
A
Abramson Cancer Center at Penn Medicine
Lead Sponsor
B
Bristol-Myers Squibb
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying acute myeloid leukemia (AML) in adults aged 50 and older to better understand physiologic age, which considers overall health rather than just calendar age. This observational study aims to evaluate how physiologic age relates to treatment outcomes like toxicity, early death, remission, and long-term survival for patients receiving intensive or non-intensive AML treatment. Participants will be assessed at the start of treatment and followed up at 14 days and one month after treatment begins. The study will measure physical function, depression, cognition, frailty, and patient-reported outcomes, along with albumin levels as a potential biomarker. These assessments will help create a screening tool to predict treatment risks and outcomes. During the study, patients will complete questionnaires and physical and cognitive evaluations at specified times. Researchers will monitor survival at one year, short-term mortality at 30 and 60 days, treatment toxicities, and remission rates. The study focuses on tracking changes in physical function over time to better understand the effects of AML treatment in older adults.
CONDITIONS
Brief Title
Assessment of Geriatric Evaluations Impact on New AML Guidance
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of AML confirmed by peripheral flow cytometry or bone marrow biopsy
- Newly diagnosed and considered for a new line of treatment
- Age 50 years or older
- Performance status of 0, 1, or 2
You will not qualify if you...
- Unable to understand or sign a written informed consent
- Unable to complete questionnaires independently or without help
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 month after treatment
Participants undergo baseline and serial assessments of physical function, depression, cognition, frailty, and other health measures to evaluate physiologic age and treatment effects over time.
Visits at baseline, 14 days after treatment, and 1 month after treatment
Duration - 60 days after treatment
Participants are observed for clinical outcomes including survival and treatment toxicities with assessments at 30 days and 60 days after treatment.
Visits at 30 days and 60 days after treatment
Trial Site Locations
Total: 1 location
1
Abramson Cancer Center at University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
C
Colleen Redlinger
C
Catherine Lai, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here